Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

US Patent 11426460 · Granted Aug 30, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CTLA-4 antibodies and methods of use thereof2025
Anti-CTLA-4 antibodies and methods of use thereof2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors2025
Imaging systems and methods2025
Hybrid nail gun2025
Neoantigens and uses thereof for treating cancer2025
Neoantigens and uses thereof for treating cancer2025